Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PHAT Phathom Pharmaceuticals

Trading 01-10 14:35:08 EST

6.95

+0.00

-0.07%

High7.11	Low6.73	Vol389.25K
Open6.91	D1 Closing6.95	Amplitude5.47%
Mkt Cap474.88M	Tradable Cap387.01M	Total Shares68.38M
T/O2.66M	T/O Rate0.70%	Tradable Shares55.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"PHAT","market":"US","secType":"STK","nameCN":"Phathom Pharmaceuticals","latestPrice":6.945,"timestamp":1736537702405,"preClose":6.95,"halted":0,"volume":389247,"delay":0,"floatShares":55725606,"shares":68377360,"eps":-5.6813,"marketStatus":"Trading","change":-0.005,"latestTime":"01-10 14:35:08 EST","open":6.91,"high":7.11,"low":6.73,"amount":2659843.860582,"amplitude":0.054676,"askPrice":6.95,"askSize":25,"bidPrice":6.93,"bidSize":340,"shortable":3,"etf":0,"ttmEps":-5.6813,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1736542800000},"marketStatusCode":2,"adr":0,"listingDate":1571976000000,"exchange":"NASDAQ","adjPreClose":6.95,"preHourTrading":{"tag":"盘前","latestPrice":6.95,"preClose":6.95,"latestTime":"08:35 EST","volume":60,"amount":417,"timestamp":1736516120385},"postHourTrading":{"tag":"盘后","latestPrice":6.95,"preClose":6.95,"latestTime":"19:32 EST","volume":26576,"amount":184713.11,"timestamp":1736382726150},"volumeRatio":0.598355,"impliedVol":0.6226,"impliedVolPercentile":0.1992},"requestUrl":"/m/hq/s/PHAT/wiki","defaultTab":"wiki","newsList":[{"id":"2502868819","title":"Phathom Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2502868819","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502868819?lang=en_us&edition=fundamental","pubTime":"2025-01-10 20:50","pubTimestamp":1736513400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHAT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 10, 2025 07:50 ET (12:50 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT"],"gpt_icon":0},{"id":"2491590374","title":"Insider Sellers Might Regret Selling Phathom Pharmaceuticals Shares at a Lower Price Than Current Market Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2491590374","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491590374?lang=en_us&edition=fundamental","pubTime":"2024-12-14 22:33","pubTimestamp":1734186800,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) stock price has dropped 12% in the previous week, but insiders who sold...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phat/phathom-pharmaceuticals/news/insider-sellers-might-regret-selling-phathom-pharmaceuticals","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","PHAT"],"gpt_icon":0},{"id":"2490202338","title":"Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2490202338","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490202338?lang=en_us&edition=fundamental","pubTime":"2024-12-12 22:39","pubTimestamp":1734014342,"startTime":"0","endTime":"0","summary":"PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. Given concerns regarding the decreasing pace of U.S. employment and the associated concerns that U.S. interest rates may have been maintained at levels higher than necessary to moderate the pace of inflation, U.S. equity markets fluctuated during the summer and partially reversed their year-to-date gains. The S&P 1500 Health Care Index appreciated 6.1% in the third quarter, outperforming the S&P 500, which gained 5.9%. While the fund advanced in the quarter, it underperformed the index. Stock selection within medtech and pharmaceuticals contributed to the most value. Relative performance was negatively impacted by security selection in biotechnology and health care providers and services, as well as underweights in life sciences tools and services. In addition, please check the fund’s top five holdings to know its best picks in 2024.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SyuP9bZeVxmx3vC9hOLnPQ--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/9e64f5ca517452c881a762956e9cc2b7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SyuP9bZeVxmx3vC9hOLnPQ--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/9e64f5ca517452c881a762956e9cc2b7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/believe-growth-potential-phathom-pharmaceuticals-143902530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","USJW.SI","NVIW.SI","TQQQ","USAW.SI","NERD","NQmain","TSYW.SI","PHAT","QID",".IXIC","BK4007","PSQ","SQQQ","MNQmain"],"gpt_icon":1},{"id":"2490438626","title":"Craig-Hallum Remains a Buy on Phathom Pharmaceuticals (PHAT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2490438626","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490438626?lang=en_us&edition=fundamental","pubTime":"2024-12-12 21:57","pubTimestamp":1734011851,"startTime":"0","endTime":"0","summary":"In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report). The ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-remains-a-buy-on-phathom-pharmaceuticals-phat-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-remains-a-buy-on-phathom-pharmaceuticals-phat-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","PHAT"],"gpt_icon":0},{"id":"2490789693","title":"Phathom Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2490789693","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490789693?lang=en_us&edition=fundamental","pubTime":"2024-12-12 02:21","pubTimestamp":1733941260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHAT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2024 13:21 ET (18:21 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT"],"gpt_icon":0},{"id":"2490868589","title":"Phathom Pharmaceuticals Files US FDA Petition to Seek Voquezna Exclusivity Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2490868589","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490868589?lang=en_us&edition=fundamental","pubTime":"2024-12-11 22:33","pubTimestamp":1733927598,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals  said Wednesday it has filed a Citizen Petition with the US Food and Drug Administration to request a 10-year New Chemical Entity exclusivity period ending May 3, 2032, for Voquezna  tablets in the Orange Book listings.The Orange Book is the common name for the organization's Approved Drug Products with Therapeutic Equivalence Evaluations publication, according to the FDA website.The company said the exclusivity period, granted under the Generating Antibiotic Incentives Now Act for other vonoprazan-based products approved in 2022, should also apply to VOQUEZNA tablets.The New Chemical Entity protection prohibits generic competition during the exclusivity period and aligns with legal and regulatory precedents, Phathom said.The company also said it expects the FDA to respond to the petition within 180 days.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2490526568","title":"BRIEF-Phathom Pharmaceuticals Submits Citizen Petition To FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2490526568","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490526568?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:35","pubTimestamp":1733924121,"startTime":"0","endTime":"0","summary":"BRIEF-Phathom Pharmaceuticals Submits Citizen Petition To FDA Dec 11 (Reuters) - Phathom Pharmaceuticals PHAT.O:PHATHOM PHARMACEUTICALS SUBMITS CITIZEN PETITION TO FDA SEEKING CORRECTION OF ORANGE BOO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nFWN3NC0NL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2490854390","title":"Phathom Pharmaceuticals submits Citizen Petition to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2490854390","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490854390?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:10","pubTimestamp":1733922650,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (PHAT) announced it has submitted a Citizen Petition, CP, with the U.S. Food and Drug Administration, FDA. The petition for...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/phathom-pharmaceuticals-submits-citizen-petition-to-fda?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/phathom-pharmaceuticals-submits-citizen-petition-to-fda?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2490932851","title":"Phathom Pharmaceuticals Inc: Exclusivity Period Is Until May 3, 2032","url":"https://stock-news.laohu8.com/highlight/detail?id=2490932851","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490932851?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:00","pubTimestamp":1733922055,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nFWN3NC0NL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PHAT"],"gpt_icon":0},{"id":"2490851939","title":"Phathom: Petition Requests Correction of Orange Book Listings for Voquezna 10 Mg,20 Mg Tablets to Accurately Reflect 10-Year Nce Exclusivity Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2490851939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490851939?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:00","pubTimestamp":1733922055,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nFWN3NC0NL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2490851687","title":"Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for Voquezna® (Vonoprazan) Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2490851687","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490851687?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:00","pubTimestamp":1733922055,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nFWN3NC0NL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2490851791","title":"Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2490851791","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490851791?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:00","pubTimestamp":1733922000,"startTime":"0","endTime":"0","summary":"Citizen Petition seeks correction of expiration date for New Chemical Entity (NCE) exclusivity on VOQUEZNA (vonoprazan) tablets Orange Book listingsPhathom believes applicable law mandates a 10-year N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/11/2995336/0/en/Phathom-Pharmaceuticals-Submits-Citizen-Petition-to-FDA-Seeking-Correction-of-Orange-Book-Listings-for-VOQUEZNA-vonoprazan-Tablets.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4016","BK4135","BK4585","BK4007","BK4588","PHAT","CP","LU1261432733.SGD","GAIN"],"gpt_icon":0},{"id":"2489586182","title":"Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround","url":"https://stock-news.laohu8.com/highlight/detail?id=2489586182","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489586182?lang=en_us&edition=fundamental","pubTime":"2024-12-06 22:35","pubTimestamp":1733495704,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals, Inc.  has been beaten down lately with too much selling pressure. While the stock has lost 54.1% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.We use Relative Strength Index , one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.The RSI reading of 25.09 for PHAT is an indication that the heavy selling could be in the process of exhausting","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/M2z0wFqvnPw7eaLU0tPuyQ--~B/aD02MzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/M2z0wFqvnPw7eaLU0tPuyQ--~B/aD02MzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/down-54-05-4-weeks-143504493.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHAT","RSI","BK4150","BK4007"],"gpt_icon":0},{"id":"2489453709","title":"Phathom Pharmaceuticals Inc : Jefferies Cuts Target Price to $17 From $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2489453709","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489453709?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:49","pubTimestamp":1733402999,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241205:nFWN3N616F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2484971799","title":"Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2484971799","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484971799?lang=en_us&edition=fundamental","pubTime":"2024-11-20 01:00","pubTimestamp":1732035611,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals, Inc.  appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 . An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.As such, the Zacks rating upgrade for Phathom Pharmaceuticals is essentially a positive comment on its earnings outlook that could h","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UYup8AGIrn99rMsHiTllqA--~B/aD04NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UYup8AGIrn99rMsHiTllqA--~B/aD04NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phathom-pharmaceuticals-phat-upgraded-buy-170011997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHAT"],"gpt_icon":0},{"id":"2482243181","title":"Phathom Pharmaceuticals (PHAT) Receives a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2482243181","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482243181?lang=en_us&edition=fundamental","pubTime":"2024-11-11 10:05","pubTimestamp":1731290746,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) on November 8 and set a price ta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/phathom-pharmaceuticals-phat-receives-a-buy-from-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/phathom-pharmaceuticals-phat-receives-a-buy-from-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT","BK4007","BK4127","SF"],"gpt_icon":0},{"id":"2481127221","title":"Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2481127221","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481127221?lang=en_us&edition=fundamental","pubTime":"2024-11-08 19:02","pubTimestamp":1731063769,"startTime":"0","endTime":"0","summary":"Net Revenues: $16.4 million for Q3 2024, representing over 120% sequential quarter-over-quarter increase.Gross Profit: $14 million, with a gross margin of 86%, an increase of about 440 basis points over last quarter.R&D Expenses: Non-GAAP R&D spend of $7.4 million, a 32% decrease compared to Q3 2023.SG&A Expenses: Non-GAAP expenses of $71.8 million for Q3 2024, with advertising costs of approximately $17.5 million.Net Loss: Non-GAAP adjusted net loss of $67.9 million or $1.05 loss per share for Q3 2024.Cash and Cash Equivalents: $335 million as of September 30, 2024.Prescriptions Filled: Over 143,000 prescriptions filled from launch through October 25th, with approximately 69,000 filled in Q3 2024.Commercial Coverage: VOQUEZNA's total covered population now captures over an estimated 120 million people or more than 80% of all US commercial lives.Phathom Pharmaceuticals Inc  successfully launched VOQUEZNA for non-erosive GERD, achieving significant market penetration with over 143,000 p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/AFsR2BeTDqarwJliTTj03A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/867ea8ef0c915a0d9ee8563b62d04207","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/AFsR2BeTDqarwJliTTj03A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/867ea8ef0c915a0d9ee8563b62d04207"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phathom-pharmaceuticals-inc-phat-q3-110249525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHAT"],"gpt_icon":0},{"id":"2481121900","title":"Phathom Pharmaceuticals  : Craig-Hallum  Raises Target Price to $27 From $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2481121900","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481121900?lang=en_us&edition=fundamental","pubTime":"2024-11-08 18:32","pubTimestamp":1731061960,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nAZN2LB0K6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PHAT"],"gpt_icon":0},{"id":"2481293132","title":"Phathom Pharmaceuticals Shares Fall After Q3 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2481293132","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481293132?lang=en_us&edition=fundamental","pubTime":"2024-11-07 23:34","pubTimestamp":1730993654,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals'  shares were down 3.3% in recent Thursday trading after the company reported a Q3 net loss of $1.05 per diluted share, wider than a loss of $0.54 a year earlier.Two analysts polled by Capital IQ projected a loss of $1.47 per share.Net revenue for the quarter ended Sept. 30 was $16.4 million, with no year-ago revenue reported.Analysts surveyed by Capital IQ expect $12.4 million.\"There were no revenues for the third quarter 2023 due to the launch of Voquezna taking place in the fourth quarter 2023,\" according to the company.Phathom received approval from the US Food and Drug Administration in July for Voquezna tablets for the relief of heartburn related to non-erosive gastroesophageal reflux disease in adults.Price: 17.41, Change: -0.59, Percent Change: -3.31","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2481184645","title":"Phathom Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481184645","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481184645?lang=en_us&edition=fundamental","pubTime":"2024-11-07 23:10","pubTimestamp":1730992243,"startTime":"0","endTime":"0","summary":"* Phathom Pharmaceuticals Inc    reported a quarterly adjusted loss of $1.32 per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -76 c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.phathompharma.com","stockEarnings":[{"period":"1week","weight":-0.1441},{"period":"1month","weight":-0.2519},{"period":"3month","weight":-0.5576},{"period":"6month","weight":-0.4034},{"period":"1year","weight":-0.1657},{"period":"ytd","weight":-0.1441}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0251},{"period":"3month","weight":0.0232},{"period":"6month","weight":0.0527},{"period":"1year","weight":0.244},{"period":"ytd","weight":0.0058}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.04372},{"month":2,"riseRate":0.8,"avgChangeRate":0.124053},{"month":3,"riseRate":0,"avgChangeRate":-0.171034},{"month":4,"riseRate":0.6,"avgChangeRate":0.127165},{"month":5,"riseRate":0.6,"avgChangeRate":-0.027307},{"month":6,"riseRate":0.6,"avgChangeRate":0.044836},{"month":7,"riseRate":0.8,"avgChangeRate":0.051978},{"month":8,"riseRate":0.6,"avgChangeRate":0.096985},{"month":9,"riseRate":0.4,"avgChangeRate":0.002397},{"month":10,"riseRate":0.2,"avgChangeRate":-0.078312},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.142586},{"month":12,"riseRate":0.666667,"avgChangeRate":0.072415}],"exchange":"NASDAQ","name":"Phathom Pharmaceuticals","nameEN":"Phathom Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Phathom Pharmaceuticals(PHAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Phathom Pharmaceuticals,PHAT,Phathom Pharmaceuticals股票,Phathom Pharmaceuticals股票老虎,Phathom Pharmaceuticals股票老虎国际,Phathom Pharmaceuticals行情,Phathom Pharmaceuticals股票行情,Phathom Pharmaceuticals股价,Phathom Pharmaceuticals股市,Phathom Pharmaceuticals股票价格,Phathom Pharmaceuticals股票交易,Phathom Pharmaceuticals股票购买,Phathom Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Phathom Pharmaceuticals(PHAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}